Canadian Treat-and-Extend Trial With Ranibizumab in nAMD Patients: CANTREAT 36-Month Extension Results

Related

• 

  A Real-World Analysis in 49,485 Eyes of Visual Acuity Outcomes and Anti-VEGF Therapy Intensity in Neovascular AMD Patients

  David F. Williams, MD, MBA

  Annual Meeting Talks

  2018

• 

  Expert Panel:PDS

  Robert A. Mittra, MD, FASRS

  Dante Joseph Pieramici, MD

  Aleksandra V. Rachitskaya, MD, FASRS

  Margaret A. Chang, MD, MS

  Carl C. Awh, MD, FASRS

  Annual Meeting Talks

  2024

• 

  Baseline DR Severity and Time to DME Resolution in Patients Treated With Ranibizumab in the RIDE and RISE Clinical Trials

  Katherine E Talcott, MD

  Annual Meeting Talks

  2021